In yesterday’s Wall Street session, Allogene Therapeutics Inc (NASDAQ:ALLO) shares traded at $4.66, up 3.67% from the previous session.
ALLO stock price is now 12.48% away from the 50-day moving average and 18.83% away from the 200-day moving average. The market capitalization of the company currently stands at $787.96M.
, while ‘Citigroup’ rates the stock as ‘Buy’
In other news, Parker Geoffrey M., CHIEF FINANCIAL OFFICER bought 190 shares of the company’s stock on Jan 30 ’24. The stock was bought for $683 at an average price of $3.60. Upon completion of the transaction, the CHIEF FINANCIAL OFFICER now directly owns 819,590 shares in the company, valued at $3.82 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 18 ’23, Director MESSEMER DEBORAH M. sold 18,640 shares of the business’s stock. A total of $50,317 was realized by selling the stock at an average price of $2.70. This leaves the insider owning 62,456 shares of the company worth $0.29 million. A total of 38.28% of the company’s stock is owned by insiders.
During the past 12 months, Allogene Therapeutics Inc has had a low of $2.23 and a high of $6.89. As of last week, the company has a debt-to-equity ratio of 0.19, a current ratio of 12.58, and a quick ratio of 12.58. The fifty day moving average price for ALLO is $4.1698 and a two-hundred day moving average price translates $3.9192 for the stock.
The latest earnings results from Allogene Therapeutics Inc (NASDAQ: ALLO) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.43, beating analysts’ expectations of -$0.45 by 0.02. This compares to -$0.71 EPS in the same period last year. The net profit margin was -202366.25% and return on equity was -42.02% for ALLO. The company reported revenue of $44000.0 for the quarter, compared to $40000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 10.0 percent. For the current quarter, analysts expect ALLO to generate $30k in revenue.
Allogene Therapeutics Inc(ALLO) Company Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
